SILO · XBRL financial data

Silo Pharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SILO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Revenue	18	18*	18	18	18	18*	18	18	18	18*	18	0*
Cost of revenue	1	1*	1	1	1	1*	1	1	21	21*	21	0*
Gross profit	17	17*	17	17	17	17*	17	17	(3)	(3)*	(3)	0*
Research and development	174	337*	318	393	518	1,076*	594	717	544	306*	1,013	298
Selling, general and administrative	—	year only	64	51	—	—	—	—	—	—	—	—
Total operating expenses	790	1,180*	896	1,019	1,027	1,830*	1,111	1,265	1,149	784*	1,592	929
Operating income (loss)	(773)	(1,164)*	(880)	(1,003)	(1,010)	(1,813)*	(1,094)	(1,249)	(1,151)	(787)*	(1,595)	(929)
Interest income	—	—	—	—	—	—	—	—	—	year only	0	1*
Interest expense	1	0*	2	2	1	0*	2	2	1	33*	3	3
Net income (loss)	(660)	(1,121)*	(802)	(932)	(929)	(1,731)*	(1,031)	(1,204)	(1,110)	(882)*	(1,647)	(833)
Earnings per share, basic USD per share	(0.21)	(0.39)*	(0.28)	(0.31)	(0.22)	(0.39)*	(0.23)	(0.19)	(0.12)	—	(0.12)	(0.76)
Earnings per share, diluted USD per share	(0.21)	(0.39)*	(0.28)	(0.31)	(0.22)	(0.39)*	(0.23)	(0.19)	(0.12)	—	(0.12)	(0.76)
Weighted average shares, basic thousands of shares	3,109	2,901*	2,867	3,053	4,302	4,484*	4,484	6,280	9,331	—	13,709	1,099
Weighted average shares, diluted thousands of shares	3,109	2,901*	2,867	3,053	4,302	4,484*	4,484	6,280	9,331	—	13,709	1,099

† Share count changed about 1/10 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (SILO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Cash and cash equivalents	200	3,524	2,668	4,506	4,861	3,906	3,137	4,334	3,918	4,749	3,903	3,277
Short-term investments	8,571	4,141	4,076	3,102	3,154	3,175	2,315	1,926	1,949	2,110	2,130	1,950
Prepaid and other current assets	80	16	134	120	246	31	153	113	226	209	529	281
Total current assets	8,921	7,681	6,878	7,729	8,262	7,111	5,604	6,373	6,164	7,388	6,804	5,714
Total assets	8,987	7,746	6,941	8,038	8,567	7,412	5,900	6,653	6,385	7,605	7,018	5,952
Accounts payable	144	—	—	—	—	—	—	—	—	—	—	—
Total current liabilities	679	776	874	1,323	1,045	1,656	1,185	1,050	708	650	705	1,066
Total liabilities	1,490	1,569	1,649	2,081	1,784	2,378	1,889	1,735	1,376	1,300	1,336	1,066
Accumulated deficit	(9,751)	(10,872)	(11,673)	(12,605)	(13,534)	(15,265)	(16,296)	(17,500)	(18,611)	(19,492)	(21,140)	(21,972)
Total stockholders' equity	7,497	6,177	5,292	5,958	6,782	5,034	4,011	4,917	5,009	6,305	5,682	4,886
Total liabilities and equity	8,987	7,746	6,941	8,038	8,567	7,412	5,900	6,653	6,385	7,605	7,018	5,952
Common shares outstanding (cover page) thousands of shares	3,109	2,844	2,803	4,484	4,484	4,484	4,484	9,401	13,318	14,167	16,267	1,588

† Share count changed about 1/10 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (SILO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Net income (loss)	(660)	(1,121)*	(802)	(932)	(929)	(1,731)*	(1,031)	(1,204)	(1,110)	(882)*	(1,647)	(833)
Stock-based compensation	379	161*	173	168	170	395*	178	(161)*	47*	52*	57	39*
Net cash from operating activities	(1,072)*	(910)*	(838)	(732)*	(1,347)*	(917)*	(1,640)	(1,285)*	(955)*	(780)*	(823)	(782)*
Net cash from investing activities	1,259*	4,429*	98	954*	(40)*	(38)*	871	388*	(95)*	(520)*	(24)	183*
Proceeds from issuing common stock	—	—	—	—	—	0*	—	—	—	—	—	—
Net cash from financing activities	(146)*	(194)*	(115)	1,616*	1,742*	0*	—	—	635*	2,131*	—	—

† Share count changed about 1/10 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Silo Pharma	3,277	0*	(782)*	1.6M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Skinvisible	4	5	2.2*	5.4M	—	Q2 FY26 10-QJun 30, 2026
Xenetic Biosciences	6,472	661	(875)*	2.3M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Adia Nutrition	128	485	(109)*	94.4M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Viskase Holdings	7,747	95,279	454*	14.3M	—	Q3 FY26 10-QSep 30, 2026
Aspira Women's Health	477	17	(2,010)*	46.6M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Creative Medical Technology Holdings	8,714	0	(1,472)*	6.6M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Target Group	14	1,381	(223)*	617.0M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Soligenix	9,811	not reported	(1,707)*	21.8M	5.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.